Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Kevin R. Dillon"'
Autor:
Steve Rough, Stan S. Kent, Kristine K. Gullickson, Kristen Jurakovich, Philip Brummond, Toni Fera, William W. Churchill, Christine Marchese, Tricia A. Meyer, Brian C. O’Neal, Jennifer Keonavong, David F. Chen, Richard K. Ogden, Lynn Eschenbacher, John S. Clark, Rafael Saenz, Doina Dumitru, Lee B. Murdaugh, Kevin R. Dillon, Christopher R. Fortier, Jacob Smith
Publikováno v:
American Journal of Health-System Pharmacy. 74:325-348
Controlled substances (CS) diversion in health systems can lead to serious patient safety issues, harm to the diverter, and significant liability risk to the organization. Diversion driven by addiction puts patients at risk of harm, including inadequ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd6e1a64ddff24b5471aeddb7295db2c
https://doi.org/10.2146/ajhp160919
https://doi.org/10.2146/ajhp160919
Publikováno v:
Mayo Clinic Proceedings. 87:674-682
Mayo Clinic has been involved in an ongoing effort to prevent the diversion of controlled substances from the workplace and to rapidly identify and respond when such diversion is detected. These efforts have found that diversion of controlled substan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4d087df2927ad5970618f350649a2478
https://doi.org/10.1016/j.mayocp.2012.03.013
https://doi.org/10.1016/j.mayocp.2012.03.013
Autor:
Paul R. Casner, Kevin R. Dillon
Publikováno v:
The Journal of Clinical Pharmacology. 30:715-719
The hydrochlorothiazide component of Maxzide (Lederle Laboratories, Pearl River, NY) has been shown to be more bioavailable than the hydrochlorothiazide component of Dyazide (Smith, Kline and French Laboratories, Philadelphia, PA). The authors compar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ceef6f834f176f01d55aa09c35f4698
https://doi.org/10.1002/j.1552-4604.1990.tb03632.x
https://doi.org/10.1002/j.1552-4604.1990.tb03632.x
Autor:
Steven H. Dzierba, Patrick C. Farley, Dominick A. Caselnova, Kevin R. Dillon, Michael S. O'Neill
Publikováno v:
American Journal of Health-System Pharmacy. 42:1348-1352
The implementation of clinical pharmacy services in an outpatient oncology clinic is described. An oncologist hired by the department of internal medicine and the director of the department of pharmacy designed the program. Both departments agreed th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ec175741ef321a9cb08032b91c05ac72
https://doi.org/10.1093/ajhp/42.6.1348
https://doi.org/10.1093/ajhp/42.6.1348
Autor:
Kevin R. Dillon, Paul R Casner
Publikováno v:
Journal of clinical pharmacology. 28(1)
A total of 175 physicians were surveyed by questionnaire before a Clinical Pharmacology Consult Service was started. Of those that responded, 72% thought the service would be helpful, although 40% said they would use the service no more than once a m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0153c2d8c3aba1d3900600cfa979dc8e
https://pubmed.ncbi.nlm.nih.gov/3350990
https://pubmed.ncbi.nlm.nih.gov/3350990
Publikováno v:
The Journal of antimicrobial chemotherapy. 24(4)
We compared the therapeutic outcome in patients with normal renal function managed with either individualized pharmacokinetic (PK) dosing or standard (every 12 h) dosing of amikacin. A total of 82 patients with confirmed or suspected infectious proce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb41b37986f29c73157bd9fa6f7d5d6c
https://pubmed.ncbi.nlm.nih.gov/2693431
https://pubmed.ncbi.nlm.nih.gov/2693431